Potassium Binder Dosing for Hyperkalemia Management

Initial Treatment and Efficacy

The onset of action of sodium zirconium cyclosilicate (Lokelma) begins within 1 hour of administration, making it suitable for more rapid potassium reduction 1
Sodium zirconium cyclosilicate (Lokelma) consistently demonstrated a mean reduction of 1.1 mEq/L in serum potassium in clinical trials 1
Patiromer (Veltassa) has a slower onset of action (approximately 7 hours) compared to SZC (1 hour) 1
Clinical trials have demonstrated a dose-dependent response with SZC, with increasing effectiveness at higher doses 1
Maintenance doses of 5 g, 10 g, and 15 g once daily of sodium zirconium cyclosilicate (Lokelma) effectively maintained normal potassium levels (3.5-5.0 mEq/L) for up to 28 days 1
In the HARMONIZE trial, SZC demonstrated a mean change of 1.1 mEq/L in serum potassium reduction with the standard initial treatment protocol 1

The most common adverse effects of sodium zirconium cyclosilicate (Lokelma) include mild to moderate edema (particularly with higher doses) and hypokalemia 1, 2
Regular monitoring of serum magnesium is recommended for patients taking patiromer (Veltassa), as hypomagnesemia occurred in 7.2% of patients in clinical trials 3
Monitor for hypokalemia, which occurred in 5.6% of patients during long-term treatment with patiromer (Veltassa) 3

Regular monitoring of serum potassium is essential to avoid hypokalemia and to guide dose adjustments 1